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2INTRODUCTION
Retinoblastoma is the most common primary intraocular malignancy of
childhood [1]. On a global scale, there are 11 cases per million children, 5
years and younger with this tumour. In India, there are 0.6 cases per 1, 00,000
children. 9-10 % of all Pediatric cancer patients (<14 years) in India have
retinoblastoma [2].
Retinoblastoma was first described in 1597, and prognosis was dismal
through the nineteenth century, at which time enucleation became more
widely accepted [3]. In the 20th century, survival has dramatically increased
from around 5 percent to over 95 percent in the developed countries, making
retinoblastoma one of the success stories in childhood cancer [4].
When retinoblastoma remains confined to the eye, it has one of the
best survival rates of all the childhood cancers, but once the spread occurs
outside the globe, the treatment needs to be more aggressive and many
children do not survive. Management of the child with metastatic disease
remains a considerable challenge to all concerned [5]. An early diagnosis is,
therefore, of paramount importance in the survival of the child.
3HISTORICAL BACKGROUND
Peter Pawius of Amsterdam provided the first description of a tumor
resembling retinoblastoma in 1597. The tumor was described as filled with a
"substance similar to brain tissue mixed with thick blood and like crushed
stone” [6].
In 1805, William Hey coined the term fungus haematodes, which he
used to describe as a fungating mass affecting the globe of the eye and
destroying its internal organization [7]. In 1809, Wardrop gave the first
accurate description of retinoblastoma and concluded that the tumor arose
from the retina. He advocated early enucleation [8]. In 1864, Virchow named
the tumor a glioma of the retina, supporting glial cells as the cell of origin of
the tumor [9].
Flexner (1891) and Wintersteiner (1897) described the histology of
retinoblastoma. The rosettes were named after them [10]. The term
retinoblastoma was coined by Verhoeff (1922) [11]. Von Graffe (1884)
advocated enucleation of eye with long optic stump. Hilgartner (1903) first
used external beam radiotherapy and Kupfer (1953) used chemotherapy for
retinoblastoma. Reese- Ellsworth (1958) proposed a classification of
retinoblastoma [12].
4EPIDEMIOLOGY
Retinoblastoma is the most frequent neoplasm of the eye in childhood
and accounts for 3% of all pediatric cancers [13]. Worldwide the incidence of
retinoblastoma is 1 in 14,000 to 18,000 live births, depending upon the
country. 250-300 new cases are diagnosed yearly in western countries [14].
Retinoblastoma occurs primarily in children less than 5 years, with a median
age of diagnosis of 24 months in children with unilateral disease and 9-12
months in children with bilateral disease [15]. There is no racial of gender
predilection for retinoblastoma. In 60% of cases, the disease is unilateral; of
these cases 15% are hereditary. Retinoblastoma is bilateral in about 40% of
cases. All bilateral and multifocal unilateral forms are hereditary [16].
The incidence rates are similar in North America, Europe and
Australia, higher in Central and South America and even higher in Asia and
Africa. This pattern supports the hypothesis of higher retinoblastoma
incidence in less industrialized countries. The varied incidence is due to
difference in occurrence of unilateral non-heritable disease. The incidence of
heritable form is relatively constant. Providing strong evidence that
environmental influences play little role in the etiology of the hereditary
forms of this tumour [17].
5PATHOGENESIS
Retinoblastoma arises from the malignant transformation of primitive
retinal cells due to mutation in the Rb gene in chromosome 13q14 [18].
Knudson’s two hit hypothesis:
In 1971, Knudson proposed that a developing retinoblast must acquire
mutations in both cellular copies of the Rb gene for retinoblastoma to
develop. This concept also established that “recessive” cancer genes, or the
loss of tumor suppressor genes, can predispose to cancer by autosomal-
dominant inheritance, although they function in a recessive manner at the
cellular level [19].
Genetic forms of retinoblastoma:
1. Somatic/Non-heritable: The most common presentation of
retinoblastoma is the unilaterally affected child with no family history.
These children usually have no germline mutation in the Rb gene, they
do not develop tumors in the second eye, they are not predisposed to
second primary cancers, and they do not transmit the disease to their
children [20]. Nonheritable retinoblastoma accounts for about 60
percent of cases and is due to two separate somatic mutations of both
cellular copies of the Rb gene in the same retinoblast.
62. Germline/Heritable: About 40 percent of all retinoblastoma patients
have a germline mutation in the Rb gene, although only about 7
percent have a positive family history. Therefore, most patients with
heritable retinoblastoma are sporadic cases with a new germline
mutation [21]. The heritable form of retinoblastoma is associated with
multiple, bilateral eye tumors. In addition, these patients are at risk for
second primary cancers like osteosarcoma, soft tissue sarcoma and
other mesenchymal tumours, brain tumour, lung and bladder cancer
and transmission of the disease to their offspring in an autosomal-
dominant fashion. About 15 percent of patients with unilateral disease
carry a germline mutation, and they are still at risk for second tumors
and hereditary transmission [22].
Retinoblastoma gene: Rb gene on chromosome 13q14 is a large gene
(27 exons spanning 200 kilobases of DNA) which is now known to be
mutated in all retinoblastomas, as well as some osteosarcomas and other
retinoblastoma-associated cancers [23]. Rb gene is critical for normal cell
growth and homeostasis throughout the body. In most tissues, loss of Rb leads
to apoptosis (programmed cell death) by triggering the p53 pathway, thereby
preventing malignant transformation. This explains why both the Rb cell
cycle pathway and the p53 apoptosis pathway are disrupted in most cancers.
7Retinoblastoma protein: The product of Rb gene is a 110-kd nuclear
phosphoprotein .  Rb protein is central to regulating cell division throughout
the body and is pathologically inactivated in the vast majority of all cancers.
The Rb protein localizes to the nucleus and can exist in both an active
hypophosphorylated form and an inactive hyperphosphorylated form. When
active, the Rb protein arrests the cell cycle by blocking the expression of
genes involved in DNA synthesis and cell division. When the Rb protein is
hyper phosphorylated, these cell cycle genes are unopposed in promoting cell
division. Cyclin dependent kinases phosphorylate the Rb protein in a highly
regulated manner that normally allows cells to divide only under appropriate
physiologic circumstances [24].
RISK FACTORS
1. Family history: Risk of retinoblastoma is substantially increased if
either of a child’s parents had prior retinoblastoma. The risk is more
pronounced if the family member had bilateral disease, multifocal
intraocular disease or both.
82. Advanced parental age: The parents of children who develop
sporadic hereditary retinoblastoma tend to be slightly but significantly
older age. Such parents are more likely to produce spermatocytes or
oocytes with increased chromosomal fragility which lead on to
chromosomal deletions or other defects that inactivate retinoblastoma
gene [25].
3. Invitro fertilization: There  is  a 5  to  7  fold  increase  in  the  risk  of
developing retinoblastoma in children born of invtro fertilization.
4. Potential mechanism of retinoblastoma tumor development was
proposed in response to the observation that spontaneous unilateral
retinoblastoma may be more frequent in non-industrialized countries.
a) Human papilloma virus: The increased incidence of non-
heritable form of retinoblastoma in tropical regions may
possibly be due to viral etiology (Human papilloma virus), that
caused pRB inactivation by the oncoprotein HPV E7 [26].
b) Low folate intake during pregnancy was also postulated to play
a role in the risk of retinoblastoma
c) Mother exposed to insect or garden sprays during pregnancy
and x-rays with direct fetal exposure and father employed as a
metal worker.
9PATHOLOGY
Retinoblastoma probably arises from primordial retinoblasts which
have the potential to differentiate along the lines of photoreceptors or Mueller
cells.
Macroscopically the tumour can present as one of the following:
1. Endophytic: Tumour arises from the inner retina and invades the
vitreous. Tumour cells may deposit on the lens, zonules, iris and
corneal endothelium, angle and aqueous veins.
2. Exophytic: Tumour arises from the outer retinal layer and growing
towards the choroid inducing retinal elevation and exudative retinal
detachment. Retinal vessels are seen over the surface. It can invade
bruch’s membrane, ciliary vessels, choroid and orbital nerves [27].
3. Mixed: common presentation
4. Diffuse:   Least common presentation with diffuse growth within the
retina with no obvious mass leading to late presentation and difficult
diagnosis
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5. Spontaneous regression: This is due to tumour necrosis,
immunological reaction, hormonal influence, tumour cell
differentiation and phthisis bulbi [28].
6. Necrotic: This occurs due to the rapid growth of tumour tissue and is
associated with advanced histological features and therefore poor
prognosis.
Microscopically, it consists of three areas. Blue areas representing
viable tumour cells, pink areas showing necrosis and purple areas containing
dystrophic calcification [29].
Retinoblastoma consists of small- to medium-sized round cells with
large nuclei and scant cytoplasm. Well-differentiated tumors may have the
following features:
? Flexner-Wintersteiner rosettes: it contains abortive rods and cones.
Clusters of cuboidal or short columnar cells arranged around a central
lumen. The nuclei are displaced away from lumen.
? Homer-Wright rosettes: It contains radially arranged tumour cells
with neural filaments filling the central space. It represents
neuroblastic differentiation. It is characteristic of neuroblastoma and
medulloepithelioma but can also be seen in retinoblastoma.
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? Fleurettes: It show advanced photoreceptor differentiation having
bouquet like appearance.
Trilateral retinoblastoma:  Bilateral retinoblastoma with
pinealoblastoma occurs in 2-3% in bilateral familial retinoblastoma.
Retinocytoma:
These benign tumors were initially called retinoma and spontaneously
regressed retinoblastoma. In 1983, the first pathologic description of this
benign variant was published and the term "retinocytoma" was proposed. The
tumor was composed of neuronal cells showing photoreceptor differentiation,
including large number of fleurettes and some glial cells. Retinocytomas have
been reported in persons with germline mutations and, when present, have the
same genetic implication as a typical retinoblastoma [30].
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CLINICAL FEATURES
Clinically, Retinoblastoma begins as a small, transparent lesion in the
sensory retina. As the tumour enlarges, it becomes opaque and develops a
dilated retinal feeding artery and draining vein, and secondary retinal
detachment can occur.
The most common presenting features are leucocoria and strabismus.
In advanced intraocular disease, buphthalmos, spontaneous hyphaema,
neovascular glaucoma, pseudo hypopyon and orbital cellulitis like picture can
occur. In advanced extraocular disease, proptosis and systemic metastasis to
bone, meninges, liver, pleura, lymph nodes etc., can occur. Advanced
presentation is seen more commonly in less developed countries than in
developed countries as per various studies.
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Sign or symptom
New
York
n=900
[31]
AIIMS
Delhi
n=392
[32]
LVPEI
N=46[33]
Eastern India
n=42
[34]
North
India
N=47
[35]
Beijing
n=1234
[36]
Leucocoria 56.2 72.2 71 20 17 67.2
Strabismus 23.6 10 6 6.1 4.4
Red eye 7 1.26 2 4 4.5 5.3
Poor vision 5.2 0.25 12 4 - 10.8
Orbital cellulitis 3 0.5 - 5 2.8 1.3
Hyphaema 1 0.25 - 4 - -
Routine
examination 3 1.5 - -
Heterochromia 1 0.25 - - -
Pseudohypopyon 0.5 0.76 2 - -
Nystagmus 0.5 - - 2.8 -
Proptosis - 13 7 3 68 2.1
Iris nodule - 0.25 - - -
Phthisis bulbi - 0.5 2 2 - -
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CLASSIFICATION
An ideal classification system for retinoblastoma should include two
components: grouping and staging. Grouping is a clinical system of
prognosticating organ salvage while staging prognosticates survival [37].
REESE ELLSWORTH CLASSIFICATION :
According to the chance of preserving the eye using external beam
radiotherapy:
Group 1 (very favorable for saving [or preserving] the eye)
? 1A: one tumor, smaller than 4 disc diameters (DD), at or behind the
equator
? 1B: multiple tumors smaller than 4 DD, all at or behind the equator
Group 2 (favorable for saving [or preserving] the eye)
? 2A: one tumor, 4 to 10 DD , at or behind the equator
? 2B: multiple tumors, 4 to 10 DD, all at or behind the equator
Group 3 (doubtful for saving [or preserving] the eye)
? 3A: any tumor in front of the equator
? 3B: one tumor, larger than 10 DD, behind the equator
15
Group 4 (unfavorable for saving [or preserving] the eye)
? 4A: multiple tumors, some larger than 10 DD
? 4B: any tumor extending anteriorly (toward the front of the eye) to the
ora serrata (front edge of the retina)
Group 5 (very unfavorable for saving [or preserving] the eye)
? 5A: tumors involving more than half of the retina
? 5B: vitreous seeding (spread of tumors into the gelatinous material that
fills the eye)
INTERNATIONAL (ABC) CLASSIFICATION SYSTEM[38]
According to the chance of preserving the eye using all modern
therapeutic approaches
Group A – Very low risk : Small discrete intraretinal tumours away from
the foveola and disc
• All tumours are 3 mm or smaller in greatest dimension, confined to the
retina and
• All tumors are located further than 3 mm from the foveola and 1.5 mm
from the optic disc
Group B – Low risk : All remaining discrete retinal tumors without seeding
• All tumors confined to the retina not in group A
• Any tumor size and location with no vitreous or subretinal seeding
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Group C – Moderate risk : Discrete local disease with minimal focal
subretinal or vitreous seeding
• Tumor(s) must be discrete
• Subretinal fluid, present or past without gross seeding, involving up to
one quadrant of retina
• Local subretinal seeding, present or past, less than 5 mm from the
tumor
• Focal vitreous seeding close to discrete tumor
Group D – High risk : Diffuse disease with significant vitreous and/or
subretinal seeding
• Tumor(s) may be massive or diffuse
• Subretinal fluid, present or past, up to total retinal detachment
• Diffuse subretinal seeding, may include subretinal plaques or tumor
nodules
• Diffuse or massive vitreous disease, may include “greasy” seeds or
avascular tumor or masses
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Group E – Very high risk : Presence of any one or more of these poor
prognosis features
• Tumor touching the lens69
• Neovascular glaucoma
• Tumor anterior to anterior vitreous face involving ciliary body or
anterior segment
• Diffuse infiltrating retinoblastoma
• Opaque media from hemorrhage
• Aseptic orbital cellulitis
• Phthisis bulbi
INTERNATIONAL RETINOBLASTOMA CLASSIFICATION:
STAGING SYSTEM –
A substaging according to the histopathological features of enucleated
specimens may further help to differentiate patients with intraocular disease.
Stage 0 : Patients treated conservatively (subject to presurgical
ophthalmologic classifications)
Stage l : Eye enucleated, completely resected histologically
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Stage II : Eye enucleated, microscopic residual tumor
Stage III : Regional extension
a) Overt orbital disease
b) Preauricular or cervical lymph node extension
Stage IV : Metastatic disease
a) Hematogenous metastasis:
1. single lesion
2. multiple lesions
b) CNS extension:
1. Prechiasmatic lesion
2. CNS mass
3. Leptomeningeal disease
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CLINICAL WORKUP
Clinical workup starts with detailed history taking includes presenting
complaints, family history and previous treatment if any. Ocular examination
includes visual acuity, anterior segment evaluation, and posterior segment
examination with dilated pupil upto ora serrata of both eyes. Examination
under general anesthesia is mandatory [39].
Computed tomography imaging is useful as an initial diagnostic tool in
retinoblastoma. It demonstrates hyperdense intraocular lesion with calcium
within the tumor in the vast majority of retinoblastomas, although smaller
tumors < 5 mm in thickness may not have detectable calcium. It cannot detect
optic nerve invasion, intracranial extension and pinealoblastoma [40].
MRI is the primary mode of imaging for retinoblastoma as it facilitates
detection of choroidal, scleral and optic nerve invasion. The lesion is
hyperintense in T1 and hypointense in T2 weighed images with respect to
vitreous.
B – Scan is used to assist in the diagnosis and to measure tumour size
before and after treatment. It appears as an acoustically solid mass with highly
reflective foci representing calcification.
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Metastatic survey includes physical examination for lymphadenopathy,
hepatosplenomegaly or bony swelling. Chest X-ray, peripheral smear, CSF
and bone marrow analysis are required. MRI brain and orbit for every six
months [41].
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TREATMENT
The primary goal of management of retinoblastoma is to save life.
Salvage of the organ (eye) and function (vision) are the secondary and tertiary
goals respectively [41]. The management strategy depends on the stage of the
disease – intraocular retinoblastoma, retinoblastoma with high-risk
characteristics, orbital retinoblastoma and metastatic retinoblastoma.
Management of retinoblastoma is highly individualized and is based on
several considerations - age at presentation, laterality, tumour location,
tumour staging, visual prognosis, systemic condition, family and societal
perception, and, to a certain extent, the overall prognosis and cost-
effectiveness of treatment in a given economic situation.
MANAGEMENT OF INTRAOCULAR RETINOBLASTOMA
A majority of children with retinoblastoma manifest at the stage when
the tumor is confined to the eye. About 90-95% of children in developed
countries present with intraocular retinoblastoma while 60-70% present at this
stage in the developing world [42]. Diagnosis of retinoblastoma at this stage
and appropriate management are crucial for life, eye and possible vision
salvage. The various treatment modalities available are as follows:
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Cryotherapy
It is performed for small equatorial and peripheral retinal tumors
measuring up to 4 mm in basal diameter and 2 mm in thickness. Triple freeze
thaw cryotherapy is applied at 4-6 week intervals until complete tumor
regression [43]. Cryotherapy produces a scar much larger than the tumor.
Complications of cryotherapy include transient serous retinal detachment,
retinal tear and rhegmatogenous retinal detachment
Laser Photocoagulation
Laser photcoagulation is used for small posterior tumors 4 mm in basal
diameter and 2 mm in thickness. The treatment is directed to delimit the
tumor and coagulate the blood supply to the tumor by surrounding it with two
rows of overlapping laser burns. Complications include transient serous
retinal detachment, retinal vascular occlusion, retinal hole, retinal traction,
and pre retinal fibrosis.
Thermotherapy
In thermotherapy, focused heat generated by infrared radiation is
applied to tissues at subphotocoagulation levels to induce tumor necrosis. The
goal is to achieve a slow and sustained temperature range of 40 to 60 degree
C within the tumor, thus sparing damage to the retinal vessels. Thermotherapy
provides satisfactory control for small tumors - 4 mm in basal diameter and 2
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mm in thickness. The major application of thermotherapy is as an adjunct to
chemoreduction. The application of heat amplifies the cytotoxic effect of
platinum analogues [44]. Greater level of tumour necrosis is achieved with
thermotherapy than photocoagulation.
Plaque Brachytherapy
Plaque brachytherapy involves placement of a radioactive implant on
the sclera corresponding to the base of the tumor to transsclerally irradiate the
tumor. Commonly used radioactive materials include Ruthenium 106 and
Iodine 125 [45]. The advantages of plaque brachytherapy are focal delivery of
radiation with minimal damage to the surrounding normal structures, absence
of cosmetic abnormality because of retarded bone growth in the field of
irradiation as occurs with external beam radiotherapy, reduced risk of second
malignant neoplasm and shorter duration of treatment. Plaque brachytherapy
is indicated in tumors less than 16 mm in basal diameter and less than 8 mm
thickness. Advantage of ruthenium over iodine is its improved dose
calculation and longer half-life of 6 months.
External Beam Radiotherapy
External beam radiotherapy was the preferred form of management
of mod erately advanced retinoblastoma in late 1900s. However with the
advent of newer chemotherapy protocols, external beam radiotherapy is being
used less often. Presently it is indicated in eyes where primary chemotherapy
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and local therapy has failed, or rarely when chemotherapy is contraindicated.
The major problems with external beam radiotherapy are the stunting of the
orbital growth, dry eye, cataract, radiation retinopathy and optic neuropathy
[46]. There is a high 30% chance of developing another malignancy by the
age of 30 years in such patients if they are given external beam radiotherapy
compared to a less than 6% chance in those who do not receive external beam
radiotherapy.
Chemotherapy
Chemoreduction, defined as the process of reduction in the tumor
volume with chemotherapy, has become an integral part of the current
management of retinoblastoma [47]. Chemotherapy alone is however not
curative and must be associated with intensive local therapy. Chemoreduction
coupled with focal therapy can minimize the need for enucleation or external
beam radiotherapy without significant systemic toxicity [48].
Chemoreduction in combination with focal therapy is now extensively
used in the primary management of retinoblastoma. There are different
protocols in chemotherapy. The commonly used drugs are vincristine,
etoposide and carboplatin, for 6 cycles. Standard dose chemoreduction is
provided in ICIOR groups A-C. In high dose chemoreduction, the dose of
etoposide and carboplatin is increased. This is indicated in ICIOR groups D
tumors [49]. With chemoreduction and sequential local therapy, it is now
possible to salvage many an eye and maximize residual vision.
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Combination chemotherapy with vincristine sulfate, carboplatin and
etoposide phosphate is usually administered in 6 cycles, but up to 13 cycles
are sometimes required to control the disease. Cyclosporine has been added to
these three agents in some institutions in order to overcome drug resistance.
When combined with focal therapy such as laser or cryotherapy, this
multimodality approach is generally quite successful for less advanced
tumors.
VINCRISTINE:
It is a vinca alkaloid which specifically binds to ?-tubulin and blocks its
ability to polymerize with ?-tubulin and form microtubules. Cells blocked in
mitosis undergo changes characteristic of apoptosis. Vincristine sulfate seems
to be better tolerated by children than by adults who may experience
neurological toxicity. myelosuppression is less common than with vinblastine.
Vincristine is given intravenously and precaution should be made to avoid
extravasation.
CARBOPLATIN:
Carboplatin (Paraplatin) is a platinum coordinator compound which
crosslinks DNA similar to alkylating agents. It is eliminated by renal
excretion. Major side effects include nephrotoxicity, ototoxicity, neuropathy,
hypomagnesemia, hypersensitivity reactions and hepatotoxcity.
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ETOPOSIDE:
Etoposide inhibits DNA and is eliminated via hepatic
biotransformation and excretion. Main adverse effects include allergic
reactions, hepatotoxicity, CNS toxicity, hypotension, alopecia, acute
myelogenous leukemia and mucositis in high doses.
Chemoreduction Regimen and Doses for Intraocular Retinoblastoma
Day 1: Vincristine + Etoposide + Carboplatin
Day 2: Etoposide
Standard dose (3 weekly, 6 cycles): Vincristine 1.5 mg/m22 (0.05
mg/kg for children < 36 months of age and maximum dose < 2mg), Etoposide
150 mg/m (5 mg/kg for children < 36 months of age), Carboplatin 560 mg/m2
(18.6 mg/kg for children < 36 months of age)
High-dose (3 weekly, 6-12 cycles): Vincristine 0.025 mg/Kg,
Etoposide 12 mg/Kg, Carboplatin 28 mg/Kg
There are five tumour regression patterns following treatment for
retinoblastoma with external beam radiotherapy, chemoreduction, plaque
therapy, laser photocoagulation and cryotherapy [50].  These include:
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Type 0: complete tumour disappearance leaving no scar
Type 1: tumour regression with complete calcification
Type 2: tumour regression with no calcification
Type 3: tumour regression with partial calcification
Type 4: tumour regression with flat atrophic scar
Enucleation
Enucleation is a common method of managing advanced
retinoblastoma. A substantial reduction in the frequency of enucleation has
occurred in the late last century [51]. Concurrently, there has been an increase
in the use of alternative eye- and vision-conserving methods of treatment.
Primary enucleation continues to be the treatment of choice for advanced
intraocular retinoblastoma with neovascularization of iris, secondary
glaucoma, anterior chamber tumor invasion, tumors occupying >75% of the
vitreous volume, necrotic tumors with second ary orbital inflammation, and
tumors associated with hyphema or vitreous hemorrhage where the tumor
characteristics cannot be visualized, especially when only one eye is
involved[52].
Special Considerations for Enucleation in Retinoblastoma :
? Minimal manipulation
? Avoid perforation of the eye
? Harvest long (> 15 mm) optic nerve stump
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? Inspect the enucleated eye for macroscopic extraocular extension and
optic nerve involvement
? Harvest fresh tissue for genetic studies
? Avoid biointegrated implant if postoperative radiotherapy is necessary.
Histopathologic High-risk Factors Predictive of Metastasis:
? Anterior chamber seeding
? Iris infiltration
? Ciliary body infiltration
? Massive choroidal infiltration
? Invasion of the optic nerve lamina cribrosa
? Retrolaminar optic nerve invasion
? Invasion of optic nerve transection
? Scleral infiltration
? Extrascleral extension
The reported occurrence of anterior chamber seeding (7%), massive
choroidal infiltration (12-23%), invasion of optic nerve lamina cribrosa (6-
7%), retrolaminar optic nerve invasion (6-12%), invasion of optic nerve
transection (1-25%), scleral infiltration (1-8%), and extrascleral extension (2-
13%), widely vary even in developed countries. Vemuganti and associates
have reported that 21% of the 76 eyes enucleated for advanced retinoblastoma
in India had anterior chamber seeding, 54% had massive choroidal
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infiltration, 46% had optic nerve invasion at or beyond the lamina cribrosa
and 7% had scleral infiltration or extrascleral extension.12 It is apparent that
the incidence of histopatho logic risk factors is strikingly high in developing
countries compared to the published data from developed countries.
Adjuvant Therapy
Studies on the efficacy of adjuvant therapy to minimize the risk of
metastasis initiated in the 1970s were marked by variable results and provided
no firm recommendation[53]. Recent studies show that the incidence of
metastasis was 4% in those who received adjuvant therapy compared to 24%
in those who did not. The study found that administration of adjuvant therapy
significantly reduced the risk of metastasis in patients with high-risk
histopathologic characteristics [54]. Current practice is to administer 6 cycles
of a combination of carboplatin, etoposide and vincristine (identical to the
protocol used for chemoreduction of intraocular retinoblastoma) in patients
with histopathologic high-risk characteristics [55]. All patients with extension
of retinoblastoma up to the level of optic nerve transection, scleral infiltration,
and extrascleral extension should receive high dose chemotherapy for 12
cycles and fractionated 4500 to 5000 cGy or bital external beam radiotherapy.
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Follow-up Schedule
The usual protocol is to schedule the first examination 3–6 weeks
after the initial therapy. In cases where chemoreduction therapy has been
administered, the examination should be done every 3 weeks with each cycle
of chemotherapy. Patients under focal therapy are evaluated and treated every
4-8 weeks until complete tumor regression. Following tumor regression,
subsequent examination should be 3 monthly for the first year, 6 monthly for
three years or until the child attains 6 years of age, and yearly thereafter.
MANAGEMENT OF ADVANCED RETINOBLASTOMA
Evidence of extraocular
dissemination
No
Neoadjuvant chemotherapyEnucleation
Low risk histology High risk histology
Yes No
Only orbital or
preauricular nodal
disease
CNS/systemic
metastasis
Consider high dose
chemotherapy
Alternate
treatment
Yes
Observation EBRT+/-
chemotherapy
Response
31
IMPLANT PLACEMENT IN ANOPHTHALMIC SOCKET
Enucleation in children has been associated with contraction of socket
especially at less than 1 year of age. Radiotherapy given for retinoblastoma
causes arrest in the bone development leading to anophthalmic socket
syndrome causing soft tissue loss and contracted socket [56]. Placement of an
orbital implant following enucleation for retinoblastoma is the current
standard of care. The orbital implant promotes orbital growth, provides better
cosmesis and enhances prosthesis motility. The implants could be non-
integrated (polymethyl methacrylate or silicon) or bio-integrated
(hydroxyapatite or porous polyethylene).
Placement of a biointegrated implant is generally avoided if post-
operative adjuvant radiotherapy is considered necessary. Porous implants like
hydroxyapatite can be used after 15 years of age. Although most implants
structurally tolerate radiotherapy well, implant vascularization may be
compromised by radiotherapy thus increasing the risk of implant exposure.
Use of myoconjunctival technique and custom ocular prosthesis have
optimized prosthesis motility and static cosmesis. Use of non-biodegradable
implants like silicon and PMMA with biological tissue wraps helps in
improving motility. Wrapping material can be donor sclera, bovine
pericardium or fascia lata. They are not affected by irradiation and can be
changed with age. Dermis fat graft is ideal for children as it appears to grow
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after implantation [57]. This growth of the implant may help stimulate orbital
growth, potentially leading to more symmetry between the involved and
uninvolved sides. It maintains the volume of the socket.
Determining Implant Size Based on the Size of the Natural Eye
Diameter
of
natural
eye (mm)
Volume
of
natural
eye (ml)
Volume
of
artificial
eye (ml)
Volume
deficit
remaining
(m)
Diameter of
implant to use if
unwrapped (mm)
Diameter of
implant to use
if wrapped
(mm)
20.0 4.19 2.5 1.69 15.0 13.5
20.5 4.51 2.5 2.01 15.5 14.0
21.0 4.85 2.5 2.35 16.5 15.0
21.5 5.21 2.5 2.71 17.5 16.0
22.0 5.58 2.5 3.08 18.0 16.5
22.5 5.97 2.5 3.47 19.0 17.5
23.0 6.37 2.5 3.87 19.5 18.0
23.5 6.80 2.5 4.30 20.0 18.5
24.0 7.24 2.5 4.74 21.0 19.5
24.5 7.70 2.5 5.20 21.5 20.0
25.0 8.18 2.5 5.68 22.0 20.5
25.5 8.69 2.5 6.19 23.0 21.5
26.0 9.21 2.5 6.71 23.5 22.0
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AIMS AND OBJECTIVES
The aims of this study were to analyse:
? Age incidence
? Sex distribution
? Laterality
? Modes of presentation
? Time lag between onset of symptoms and presentation
? Staging
? Management and follow-up of cases diagnosed as Retinoblastoma
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MATERIALS AND METHODS
This study was a prospective study conducted at Regional Institute of
Ophthalmology, Govt. Ophthalmic Hospital from May 2009 to November
2011. All the children who presented to our institution with features
suggestive of Retinoblastoma were included in the study after confirmation of
diagnosis. 28 consecutive patients (36 eyes) were included in the study.
Detailed clinical history was obtained regarding the presenting
complaints like appearance of “amaurotic cats’ eye”, pain, watering, redness,
protrusion of eyes, defective vision etc. The duration and progression of these
features and time lag between onset and diagnosis was obtained. Family
history regarding consanguinity, health of the siblings and occurrence of
similar features in other family members is recorded.
Ocular examination included visual acuity, slit lamp examination.
Detailed fundus evaluation after total mydriasis under general anaesthesia was
done. Investigations like B-Scan, Computed Tomography/MRI imaging of
orbit and brain was done. General examination to look for lymphadenopathy,
hepatomegaly and bony swellings was done. Metastatic work-up included
peripheral smear, bone marrow aspiration, CSF analysis, X-ray chest and
USG abdomen.
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Enucleated eyes were subjected to histopathological evaluation and
findings recorded. Children were followed up every 1 month until completion
of treatment and then every 3 months and fundus evaluation and examination
of empty socket. B-Scan was done every 3 months. CT/MRI was repeated
every 6 months.
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RESULTS AND ANALYSIS
In this study, a total of 28 cases were evaluated for the following:
Table 1:
AGE INCIDENCE
Age at presentation No. of cases Percentage
< 1 yr 7 25
1-3 yrs 15 53.57
>3yrs 6 21.43
Of the 28 cases examined, 53.57% were in the age group of 1 to 3 years
followed by 25% below 1 year and 21.43% above 3 years. The youngest child
was 1 month old with bilateral Retinoblastoma.
TABLE 2:
SEX DISTRIBUTION
Sex No. of cases Percentage
Males 13 46.43
Females 15 53.57
In our study, there were 13(46.43%) males and 15(53.57%) with the
male to female ratio of 0.82.
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TABLE 3:
LATERALITY
Laterality No. of cases Percentage
Unilateral
Right eye
Left eye
9
11
32.14
39.29
Bilateral 8 28.57
TABLE 4:
MEAN AGE AT PRESENTATION ACCORDING TO LATERALITY
Laterality
No. of cases
Percentage
Mean age at
presentation
(months)
<1 yr 1-3yrs >3yrs
unilateral 2 14 4 71.43 28.95
Bilateral 5 2 1 28.57 16.88
Retinoblastoma was unilateral in 20 cases (71.43%) and bilateral in 8
patients (28.57%). Mean age at presentation of bilateral retinoblastoma was
16.88 months.
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TABLE 5:
MODE OF PRESENTATION
Sign No. of cases Percentage
Leucocoria 18 64.29
Leucocoria+red eye 2 7.14
Proptosis 2 7.14
Leucocoria+proptosis 2 7.14
Orbital cellulitis 1 3.57
Red eye 1 3.57
Red eye after trauma 1 3.57
Pseudohypopyon 1 3.57
Leucocoria was the commonest presentation in 64.29% of patients
followed by leucocoria with red eye, proptosis and leocucuria with proptosis
in 7.14% of patients.
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TABLE 6:
TIME INTERVAL BETWEEN NOTICING OF
FIRST SYMPTOM AND DIAGNOSIS
First symptom Median lag time in weeks
Leucocoria 2 (1-5)
Leucocoria+red eye 8(4-24)
Leucocoria+proptosis 10.5(8-13)
Proptosis 11.5(10-13)
Orbital cellulitis 10
Red eye 2.5 (1-4)
The mean time lag between onset of symptom and diagnosis was 4.5
weeks.
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TABLE 7:
CLASSIFICATION OF THE TUMOUR
Group No. of eyes Percentage
A - -
B - -
C 2 5.56
D 23 63.88
E 11 30.56
About 94.44% of eyes (33) presented with advanced stage of disease.
Only 3 eyes were in the favorable staging.
TABLE 8:
CALCIFICATION IN ULTRASOUND AND CT
Calcification
Ultrasound CT
Eyes % Eyes %
Present 34 94.44 34 94.44
Absent 2 5.56 2 5.56
Calcification was equally detected by both ultrasound and CT in all
cases except 2 eyes in which both the imaging modalities could not identify
calcification.
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MODE OF
PRESENTATION
AGE AT
PRESENTATION
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TABLE 9:
EVIDENCE OF SPREAD OF TUMOUR ON MRI
Features No.of eyes Percentage
Intraocularr 29 80.55
Optic nerve invasion 3 8.33
Extraocular extension 2 5.56
Intracranial metastasis 2 5.56
The tumour was confined to the globe in 80.55% of patients but the
rest showed evidence of spread.
TABLE 10:
MODE OF TREATMENT
Treatment No. of patients Percentage
Enucleation 10 35.70
Enucleation followed by chemotherapy 8 28.57
Enucleation followed by
Chemotherapy+Radiotherapy
4 14.28
Chemotherapy 2 7.14
Chemotherapy+Radiotherapy
Followed by enucleation
2 7.14
Refused treatment 2 7.14
Majority of the patients (85.71%) had to undergo enucleation due to
the late stage of presentation.
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TABLE11:
HIGH RISK HISTOLOGICAL FEATURES
HPE
Median age at
presentation
(months)
No. of eyes
(n=26)
Percentage
No risk factors 24 15 57.69
Choroidal invasion 24 5 19.23
Scleral and Optic
nerve invasion
42 3 11.53
Optic nerve +
choroidal invasion
36 1 3.85
Optic nerve invasion 96 1 3.85
Iris infiltration 36 1 3.85
Of the 26 eyes enucleated, high risk histological features which could
lead to metastasis was found in 11 eyes (42.31%) with Choroidal invasion
being the most common feature (19.23%).
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TABLE 12:
ORBITAL IMPLANT
Implant Time ofimplant
No. of eyes
(n=26)
Percentage
No implant 19 73.08
PMMA Primary 4 15.38
PMMA Secondary 2 7.69
Dermis fat Secondary 1 3.85
Out of the 26 enucleations, 7 eyes (26.92%) were replaced by implants.
TABLE 13:
STAGE OF RETINOBLASTOMA
Stage No. of patients Percentage
0 2 7.69
l 16 61.54
ll 4 15.38
lll a 1 3.85
b - -
lV a 1 3.85
b 2 7.69
Out of 26 patients treated, sub staging showed 61.54% of patients in
stage l in whom enucleation had been done and completely resected
histologically.
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MODE OF TREATMENT
enucleation
enucleation+chemotherapy
enucleation+chemotherapy+radiotherapy
chemotherapy
chemotherapy+radiotherapy+enucleation
refused treatment
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FOLLOW UP
no rec death
refused treatment lost to follow
TABLE 14:
FOLLOW UP OF CASES:
Outcome No. of cases Percentage
No recurrence 21 75
Death 4 14.29
Refused treatment 2 7.14
Lost to follow-up 1 3.57
Cases were followed up monthly during the initial 3 months and 6 monthly
thereafter with a minimum of 3 months during study period. No recurrence
was seen in 21 patients. 4 patients died during the study period.
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DISCUSSION
In our study, age group of the patients was from 1 month to 8 years
with a mean of 26.25 months. Most of the patients presented within 3 years of
age accounting for 78.57% of cases. Our study was similar to that of
Abramson et al [31]. Studies done in India showed similar findings. A study
done by Shanmugam et al showed mean age at presentation to be 23.98+/-
23.37 months [58].
In our study, there were 13(46.43%) males and 15(53.57%) with a ratio
of 0.82. Studies by Azar et al showed no significant difference [59]. While
those by Alegria et al [60] and Kaimbo et al showed male to female ratio of
more than 1. some studies have shown female preponderance like that of
Mukhopadyaya et al [61].
Most of the patients presented with unilateral Retinoblastoma,
accounting for 71.43% (20 cases) of cases with a mean age of 28.95 months
while patients with bilateral disease presented at an earlier age with a mean of
16.88 months with the youngest being 12months of age. Similar earlier
presentation of bilateral Retinoblastoma has been seen in study by Junyang
Zhao et al (study of 470 patients) in which unilateral disease presented at
mean age of 27 months while bilateral at 15 months [36].
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Fig.1 Fundus photograph showing endophytic lesion
with vitreous seeding in Group C
Fig.2 Clinical photograph showing leucocoria in a case of
bilateral retinoblastoma
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Fig.3 Clinical photograph showing secondary glaucoma
Fig.4 Clinical photograph showing extraocular
extension of retinoblastoma
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Leucocoria was the most common presenting feature accounting for
64.29% of cases. Similar observations have been seen in various studies in
New York, Finland, Beijing [31, 36]. Studies in India also had leucocoria as
most common presenting feature. In all the studies more than 50% of patients
had leucocoria. Strabismus was not the presenting sign in our study but was
one of the significant features in studies by Abramson et al and Honavar
et al [31, 33].
Though leucocoria was seen by parents in 14.28% of patients, they were
brought to the ophthalmologist only after development of proptosis and red
eye. In one patient red eye was attributed to the trauma while leucocoria was
unnoticed. This highlights the lack of awareness of parents in identifying the
condition. Therefore it is important to educate the public and improve the
awareness among health care providers especially pediatricians.
Proptosis, pseudohypopyon and orbital cellulitis which suggest
advanced stage at presentation was seen in 21.02% of patients. These findings
have been found in studies of developing countries while in Nepal [62],
proptosis is the most common presentation. But in studies from New
York[31] and Philadelphia have recorded fewer patients with advanced
features accounting for less than 10% which necessitates the need for protocol
for screening of new born and infants periodically for retinoblastoma.
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The time lag between onset of signs and diagnosis was least in
patients with leucocoria (2weeks) as it is the most common presentation of
retinoblastoma while proptosis had the maximum time lag of 11.5 weeks. The
overall median lag was 4.5weeks. Our study showed a statistically significant
correlation (p=0.001) between presenting signs and the time lag between
onset and diagnosis. Atypical presentation like red eye, orbital cellulitis and
proptosis have been associated with delayed diagnosis.
Out of the 36 eyes, all were above group C of International
classification at the time of presentation with advanced stage being 94.44% of
eyes. Presentation at advanced stage has been seen in studies of developling
countries. Study by Sahu et al [34] showed all patients to be in the stage v of
Reese Ellsworth classification and that by Junyang et al [36] showed 84% of
eyes in advanced stage of disease. This correlates with our study. Only two
patients, who had advanced disease in one eye presented with group C in the
other. Hence enucleation was the most common modality of treatment in our
study.
Calcification was not present in both B-Scan and CT in two cases. All
other patients had calcification on both the imaging modalities. Diffuse type
of growth was seen in these patients.
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Evidence of spread of the tumour on MRI was seen in 18.45% of eyes
of which optic nerve invasion was most common accounting for 8.33% of
cases followed by intracranial metastasis and extraocular spread in 5.56%
each. These findings were not seen in CT imaging. Though calcification is
one of the most important diagnostic features of retinoblastoma which is
evident on CT, evaluation of extension and metastasis is possible only with
MRI imaging.
Fig.5 B-Scan image
showing moderate intense
echoes throughout
vitreous cavity with few
high intense echoes with
corresponding high spike
suggesting calcification
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Fig.6 CT image showing intraocular calcification
suggestive of retinoblastoma
Fig.7 CT image showing diffuse infiltrating lesion without calcification
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Fig.8 MRI image showing hyperintensity on T1 and hypointensity on
T2 in a patient with bilateral retinoblastoma
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Majority of our patients underwent enucleation (78.57%) with two
patients undergoing bilateral enucleation which correlates with studies of both
developed and developing countries in which enucleation has been the
primary modality of treatment like that by Honavar et al [33] in which 52% of
eyes were enucleated while that by Essuman et al [63] showed at least one eye
enucleated in all patients. Enucleation followed by chemotherapy (25%) was
given in patients who showed high risk histological characteristics in order to
prevent systemic metastasis. Chemotherapy and radiotherapy were given
after enucleation (14.28%) as the cut end of optic nerve showed tumour
infiltration or when there was extra scleral spread.
In 1 patient, there was no tumour regression with chemotherapy and
radiotherapy, so the eyes had to be enucleated. Parents of 2 patients refused
treatment due to fear of cosmetic disfigurement. Both were female children
with bilateral disease who needed enucleation as they were in group D and E.
Out of the 8 patients with bilateral retinoblastoma, no recurrence
during study period was seen in 3 patients. Refusal for treatment and death
was seen in two patients each. One patient in whom enucleation was done in
one eye and started on chemotherapy and radiotherapy for the other eye was
lost to follow-up.
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Classification system following treatment for the tumour showed
61.54% of patients were in stage I, though eye salvage was not possible; they
had reduced risk for metastasis and recurrence. But in 15.39% of eyes had
developed metastasis or had high risk features.
Fig.9 Gross picture showing entire vitreous cavity filled
with the tumour with calcification
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Fig.10 Microphotograph showing Flexner Wintersteiner rosettes.
Fig.11 Microphotograph showing Homer Wright rosettes
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Fig.12 Microphotograph showing optic nerve invasion by the tumour
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Fig.13 Clinical photograph
showing anophthalmic socket
Fig.14 Clinical photograph after
dermis fat graft and prosthesis
placement
Fig.15 Clinical photograph after
enucleation and placement of
primary PMMA implant
Fig.16 Clinical photograph after
placement of prosthesis
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Orbital implant was placed in 26.92% of eyes as a primary or
secondary procedure as other parents were not willing for the procedure.
PMMA with donor sclera wrapping was done as primary and secondary
procedure in 4 (15.38%) and 2 (7.69%) eyes respectively. Dermis fat graft
was placed in 1 (4%) eye as a second stage procedure. One patient in whom
secondary PMMA implant was placed after bilateral. The patients had no
other complications and there was good cosmetic outcome in all patients.
However these patients have to be followed up regularly for any complication
or recurrence. Out of the eyes in which implant was not placed, 52.63%
showed evidence of extraocular spread or optic nerve invasion while in the
rest the parents were not willing for it.
High risk histological features were seen in 42.31% of eyes enucleated
of which choroidal invasion was most common showing advanced stage of
presentation in these patients. Occurance of these high risk features correlated
with greater age at presentation. Median age at occurance of choroidal
invasion was 24months, while that of other features was > 30 months similar
to study by Gupta et al [64]. Late stage at presentation has been associated
with high risk characteristics. These patients have been associated with
systemic metastasis and increased mortality. The survival rate among 11
patients with high risk features was 72.72% while it was 100% in patients
(14) without them.
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Out of the 28 patients, no recurrence was seen in 75% of cases during
the study period. Death during the study period occurred in 14.29% (4
patients) of patients of which one patient had advanced bilateral disease and
three other patients had metastasis in  the  form  of CNS involvement in two
and iliac bone secondaries in one. Studies show improved survival rates in
developed countries. Study by Broaddus et al [65] observed the survival rate
to be 96.5% in United States while it was 69.62% in study by masood et al
[66] in Iran which is similar to our study. Chennai has recorded least survival
rate when compared to other cities according to population based cancer
registry with a mortality rate of 48% while it is more than 60% in other cities.
In our study, 3.57% (1 patient) of patients was lost to follow up while on
treatment for secondaries with chemotherapy and radiotherapy.
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SUMMARY
A total of 28 retinoblastoma patients and 36 eyes were studied over a
three year period for age at presentation, sex, laterality, presenting signs, time
lag between symptom onset and diagnosis. All patients were subjected to
detailed clinical evaluation and investigations for staging of the disease. The
treatment of these patients was recorded.
? In our study, most patients presented within 3years of age accounting
for 78.57% of cases ranging from 1 month to 8 years of age
? It was seen that the mean age at presentation was 28.95 months in
unilateral and 16.88 months in bilateral retinoblastoma.
? There was a slight female preponderance with male to female ratio
being 0.82.
? Leucocoria was the most common presenting feature accounting for
64.29% of cases.
? A significant percentage of patients (28.57%) showed advanced stage
of presentation like proptosis, secondary glaucoma and orbital
cellulitis.
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? The median time lag between onset of symptoms and diagnosis was
4.5 weeks with least for leucocoria and maximum for proptosis.
? 94.44%of patients presented with high and very high risk disease
(group D and E of International Classification System) making eye
salvage difficult. This highlights the need for effective mass
education and screening strategies which could help in early
diagnose and treatment
? 85.71% of our patients underwent enucleation which was the most
common treatment given. Additional chemotherapy with radiotherapy
was needed in patients with high risk histological characteristics which
was present in 36% of enucleated eyes.
? Sub staging of Retinoblastoma in our study showed that out of 61.54%
of patients in stage l in which enucleation had been done and
completely resected histologically.
? Orbital reconstruction in anophthalmic socket should be done with
non-biointegrated implant in all patients to improve the cosmosis and
for social rehabilitation.
? Though leucocoria is the most common presentation,
understanding the other modes of presentation is important for
timely diagnosis because survival of children is highly dependent
on the degree of advancement of the disease.
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? All children should undergo RED REFLEX TESTING as
recommended by American Academy of Pediatrics Policy 2008 for
new born, infants and children upto 5 years of age by the pediatrician
or health care provider during every visit and referred promptly to an
ophthalmologist in case of abnormalities detected. This has been
associated with decrease in extraocular and systemic metastasis
thereby improving the survival rate. Eye salvage is difficult at this
stage.
? Dilated fundus examination of children every 3 months upto 5 years of
age by an ophthalmologist is necessary in order to detect early lesions
before the onset of leucocoria so as to save the eye and improve vision.
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CONCLUSION
? Retinoblastoma has excellent prognosis for survival, eye salvage and
vision salvage with current treatment modalities. It requires integrated
approach involving adequate screening, prompt referral and a team of
ophthalmologist and pediatric oncologist at a comprehensive tertiary
care centre.
? Our study shows that patients with retinoblastoma seek treatment at
late stage of disease due to lack of awareness and delayed access to
tertiary health care. This highlights the need for improved awareness
among public and primary health care providers so that diagnosis can
be made at an early stage.
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PROFORMA
Name:                                    Age:                      Sex: M/F
IP.NO: D.O.A:
Address:
Phone no:
Informant: mother/father/relative
First sign noticed:
1. Leucocoria
2. Squint
3. Red eye
4. Proptosis
5. Reduction in vision
6. Swelling of lids
7. Others
80
Other signs noticed:
Date of first sign:
Age at first sign:
Is there family history of retinoblastoma: yes/no
Is there family history of other cancers: yes/no
Examination:
General examination:   nutrition              pallor
Lymphnodes
Other swellings
Ocular examination:
Eye affected : right/left/both
Right eye                                                        left eye
Eyelids
Conjunctiva
sclera
Cornea
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Anterior chamber
Iris
Pupil
Lens
Fundus
International Classification for Intraocular Disease
Right eye                     left eye
Group A
Group B
Group C
Group D
Group E
Investigations:     Hb: Peripheral smear:
BMA: B-Scan:
CT/MRI:
X-Ray chest:
CSF analysis:
82
Treatment:
Enucleation Primary chemotherapy
Primary chemotherapy+radiotherapy
Adjuvant chemotherapy/radiotherapy
Focal therapy
Description of treatment given:
HPE: choroidal invasion/ extrascleral invasion/ optic nerve infiltration
Classification of Retinoblastoma
Stage:    0          l         ll        llla/b      lVa/b
Follow-up:
Ocular examination:
Investigation done:
83
Survival during study period:   yes/no
Mortality:
Cause of death:
84
KEY TO MASTER CHART
M-male I- iris invasion
F-female CHE-chemotherapy
RE- right eye 1-primary
LE- left eye 2-secondary
P-proptosis L--leucocoria
R-red eye E- enucleation
PH-pseudohypopyon C-calcification
O-orbital cellulitis ON – optic nerve
Ch- choroid R-radiotherapy
CNS – central nervous system
PMMA- polymethyl methacrylate
EE- extraocular extension
MASTER CHART
S.No name age(months) sex eye presenting signs time lag(weeks) imaging MRI group treatment hpe stage implant follow-up
1 hari 24 M RE L+R 24 C E E Ch l no rec
2 sarathy 24 M LE L+R 13 NO C CNS E E+CHR+R EE+0N lVb died at 5years
3 karishma 1 F RE L 4 C D refused treatment
3 karishma 1 F LE R 4 C E refused treatment
4 pavithra 96 F LE L 3 C ON E E+CHR ON invasion ll no rec
5 isak 30 M RE L 3 C D CHR+R+E NO ON Iinvasion l 1 PMMA no rec
6 praveena 18 F RE R 1 C E E+CHR Ch invasion l no rec
7 gayathri 48 F RE L 1 C D CHR 0 no rec
8 vijay 11 M RE L 2 C D E+CHR+R no ON invasion lVb lost to follow
8 vijay 11 M LE exam 0 C CNS C CHR+R lVb lost to follow
9 chandrasekar 3 M LE L 2 C D E no ON invasion l no rec
10 siva 24 M LE L+P 8 C E E+CHR+R Ch invasion lVa bony mets.died at 6 yrs
10 siva 24 M LE enucleated 1 C D E no ON invasion lVa died at 6 years
11 dhanim ansari 36 M LE L 3 C D E+CHR no ON invasion l no rec
12 sakthi 3 F RE L+R 8 C D E no ON invasion l 2 PMMA no rec
12 sakthi 3 F LE L+R 8 C E E no ON invasion l 2 PMMA no rec
13 priya 24 F LE L 2 C D E no ON invasion l no rec
14 nithya priya 3 F RE L 2 C D CHR 0 died at 4 months
14 nithya priya 3 F LE L 2 C D CHR 0 died at 4 months
15 sumathy 36 F RE L 1 C D E no ON invasion l no rec
16 ansh 30 M LE P 13 C EE E CHE+R+E ON+EE llla no rec
17 dhanalakshmi 12 F LE L 1 C D E no ON invasion l no rec
18 surya 30 F LE L 5 C D refused treatment
18 surya 30 F RE L 5 C D refused treatment
19 pushpa 36 F LE O 10 C ON E E+CHR ON + Ch invasion ll no rec
20 sindhya 60 F LE  exam 0 C C CHR Ch invasion 0 no rec
20 sindhya 60 F RE L 1 C D E no ON invasion l 1 PMMA no rec
21 kaviya 24 F RE L 2 C D E no ON invasion l 2 dermis fat no rec
22 avinash 3 M LE L 2 C D CHR 0 no rec
22 avinash 3 M RE L 2 C ON D E+CHR ll no rec
23 shanmugam 36 M RE PH 4 C E E+CHR I l 1 PMMA no rec
24 ekavathi 36 F LE L 4 NO C D E no ON invasion l no rec
25 goutham 60 M RE P 10 C EE E E+CHR EE+ON ll died at 7 years
26 vinitha 36 F LE L 1 C D E no ON invasion l no rec
27 jehangir 18 M RE L 2 C D E no ON invasion l no rec
28 sagariya 48 M RE L 1 C D E+CHR+R Ch l 1 PMMA  no rec
